Cognitive Improvement and Alcoholism Recovery

2006 ◽  
Author(s):  
Candice Walker
Keyword(s):  
Cognitive Improvement ◽  
Alcoholism Recovery

Cognitive Improvement by Photic Stimulation in a Mouse Model of Alzheimer’s Disease

2015 ◽  
Vol 12 (9) ◽  
pp. 860-869 ◽  
Author(s):  
Yu Zhang ◽  
Furong Wang ◽  
Xianwen Luo ◽  
Li Wang ◽  
Peng Sun ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mouse Model ◽  
Photic Stimulation ◽  
Cognitive Improvement ◽  
Model Of Alzheimer’S Disease

Cognitive improvement among abstinent methamphetamine users: A 2‐year prospective longitudinal study

2021 ◽  
Author(s):  
Tong‐Yu Wang ◽  
Teng‐Teng Fan ◽  
Julia M. Lappin ◽  
Xiao‐Dong Li ◽  
Yi‐Miao Zhao ◽  
...  
Keyword(s):  
Longitudinal Study ◽  
Prospective Longitudinal Study ◽  
Cognitive Improvement ◽  
Prospective Longitudinal

Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection

2021 ◽  
Author(s):  
Qi Li ◽  
Ying Chen ◽  
Shuaishuai Xing ◽  
Qinghong Liao ◽  
Baichen Xiong ◽  
...  
Keyword(s):  
Cognitive Improvement

scholarly journals Cortical plasticity is correlated with cognitive improvement in Alzheimer’s disease patients after rTMS treatment

2021 ◽  
Vol 14 (3) ◽  
pp. 503-510 ◽  
Author(s):  
Xingxing Li ◽  
Gangqiao Qi ◽  
Chang Yu ◽  
Guomin Lian ◽  
Hong Zheng ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cortical Plasticity ◽  
Cognitive Improvement

Cognitive improvement function of aripiprazole in adolescents with first-episode and repeated-episode schizophrenia

2021 ◽  
Vol 58 ◽  
pp. 102598
Author(s):  
Xiaoshuai Ning ◽  
Lei Xia ◽  
Yudong Shi ◽  
Rui Hao ◽  
Feng Geng ◽  
...  
Keyword(s):  
First Episode ◽  
Cognitive Improvement

scholarly journals Shotgun lipidomics of liver and brain tissue of Alzheimer’s disease model mice treated with acitretin

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Anna A. Lauer ◽  
Daniel Janitschke ◽  
Malena dos Santos Guilherme ◽  
Vu Thu Thuy Nguyen ◽  
Cornel M. Bachmann ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Neurodegenerative Disorder ◽  
Amyloid Β ◽  
Lipid Homeostasis ◽  
Medical Surveillance ◽  
Shotgun Lipidomics ◽  
App Processing ◽  
Cognitive Improvement ◽  
The Impact

AbstractAlzheimer’s disease (AD) is a very frequent neurodegenerative disorder characterized by an accumulation of amyloid-β (Aβ). Acitretin, a retinoid-derivative and approved treatment for Psoriasis vulgaris, increases non-amyloidogenic Amyloid-Precursor-Protein-(APP)-processing, prevents Aβ-production and elicits cognitive improvement in AD mouse models. As an unintended side effect, acitretin could result in hyperlipidemia. Here, we analyzed the impact of acitretin on the lipidome in brain and liver tissue in the 5xFAD mouse-model. In line with literature, triglycerides were increased in liver accompanied by increased PCaa, plasmalogens and acyl-carnitines, whereas SM-species were decreased. In brain, these effects were partially enhanced or similar but also inverted. While for SM and plasmalogens similar effects were found, PCaa, TAG and acyl-carnitines showed an inverse effect in both tissues. Our findings emphasize, that potential pharmaceuticals to treat AD should be carefully monitored with respect to lipid-homeostasis because APP-processing itself modulates lipid-metabolism and medication might result in further and unexpected changes. Moreover, deducing effects of brain lipid-homeostasis from results obtained for other tissues should be considered cautiously. With respect to acitretin, the increase in brain plasmalogens might display a further positive probability in AD-treatment, while other results, such as decreased SM, indicate the need of medical surveillance for treated patients.

436 Obstructive Sleep Apnea Treatment (e.g., CPAP) Differential Effects on Cognitive Performance

SLEEP ◽  
2021 ◽  
Vol 44 (Supplement_2) ◽  
pp. A172-A173
Author(s):  
Ei Hlaing ◽  
Stephanie Clancy Dollinger ◽  
Terry Brown
Keyword(s):  
Sleep Quality ◽  
Cognitive Deficits ◽  
Daytime Sleepiness ◽  
Short Term Memory ◽  
Cognitive Tests ◽  
Subjective Sleep Quality ◽  
Cognitive Improvement ◽  
Cpap Treatment ◽  
Integrative Research ◽  
Obstructive Sleep

Abstract Introduction The efficacy of CPAP treatment for cognitive improvement among patients with OSA is inconsistent. Naegele et al. (1995) found that short term memory impairment persisted even after 4 to 6 months of CPAP; O’Donoghue et al. (2012) have reported they did not find improvement in vigilance or memory; Felver-Grant (2007) found that working memory improved but not other cognitive tests. Kanbay et al. (2015) found patients improved on the MMSE scores after 3 months of CPAP treatment. Kim et al. (2018) claimed just 3 weeks of CPAP treatment improved attention, sleep quality, and excessive daytime sleepiness (EDS). CPAP therapy has little effect on the improvement of cognitive deficits associated with OSA if the patients did not complain of daytime sleepiness (Zhou et al,, 2016). Methods Both untreated OSA patients (N=19) and ApneaLinkTM- screened controls (N=16) were administered a battery of cognitive tests before the patients started using CPAP and these two conditions were tested again after 3 months of CPAP treatment. A Fisher’s Exact Chi-Square test was used to determine if there was an association between conditions (OSA patients vs. Controls) and level of performance on cognitive tests (low vs. high scores) at the baseline and after 3 months of treatment. Results Depression scores, subjective sleep quality scores (global PSQI), EDS scores (Epworth Sleepiness Scale), and mood disturbance (Profile of Mood States) decreased after 3 months of CPAP treatment just for patients. Controls (individuals without moderate or severe OSA) performed better at the second time on phonemic fluency, immediate recall memory test, and 30 minute delayed memory recall test. Conclusion The fact that patients did not do better at time 2 on any of the cognitive tests may indicate a long term effect of hypoxia on the brain. The cognitive deficits may not reverse within the first 3 months of CPAP although self-reported depressive symptoms and perception of sleep quality and positive mood have improved when patients reported they are compliant with the treatment. Support (if any) A grant from the Center for Integrative Research on Cognitive Neural Science, Southern Illinois University Carbondale was received.

Sign in / Sign up

Export Citation Format

Share Document